Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy

Inclusion Criteria: type 2 diabetes patients with diabetic nephropathy in the range of micro- or macroalbuminuria and * HbA1c(glycosylated haemoglobin A1c \<7% * Blood pressure ≤130/80 mmHg * LDL (Low Density Lipoproteins) \<100 mg/dl * Informed consent Exclusion Criteria: * patients with diabetic nephropathy and estimated GFR \<30ml/min with Modification of Diet in Renal Disease equation (MDRD equation) * baseline potassium \> 5.2 meq/L * patients with nephrotic proteinuria defined as albumine to creatinine ratio (ACR)\> 3.5 g/g or as proteinuria \>3.5 g per 1.73 m2 per 24 hours * history or evidence of non-diabetic kidney disease * history of stroke, peripheral artery disease, coronary artery disease * history or evidence of a secondary form of hypertension * history of severe hepatic failure, malignancy, severe endocrinopathy,autoimmune disease or chronic inflammatory disease * any known bleeding or platelet disorder or platelets \<100.000/μL * heart failure in New York Heart Association(NYHA) functional class II-IV * inability or unwillingness on the part of the patient to sign the Patient Consent Form * known hypersensitivity to ramipril or to clopidogrel * Women of child-bearing potential * use of oral anticoagulants or other antithrombotic treatment * use of glitazones * patients receiving statins should be on a stable dose of at least 3 months prior to study initiation and dose should be constant during the study * any surgical or medical condition which in the opi…